NasdaqGS:ENTA

Stock Analysis Report

Executive Summary

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases.


Snowflake Analysis

Excellent balance sheet with moderate growth potential.

Share Price & News

How has Enanta Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ENTA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.6%

ENTA

4.7%

US Biotechs

9.9%

US Market


1 Year Return

-50.8%

ENTA

-0.4%

US Biotechs

-11.9%

US Market

Return vs Industry: ENTA underperformed the US Biotechs industry which returned 0% over the past year.

Return vs Market: ENTA underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

ENTAIndustryMarket
7 Day0.6%4.7%9.9%
30 Day-7.6%-6.7%-15.0%
90 Day-23.6%-8.6%-21.5%
1 Year-50.8%-50.8%0.4%-0.4%-10.0%-11.9%
3 Year52.7%52.7%9.3%6.6%12.3%5.1%
5 Year51.5%51.5%-6.4%-10.6%32.5%18.1%

Price Volatility Vs. Market

How volatile is Enanta Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Enanta Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

27.35x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ENTA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ENTA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ENTA is poor value based on its PE Ratio (27.4x) compared to the Biotechs industry average (15.4x).

PE vs Market: ENTA is poor value based on its PE Ratio (27.4x) compared to the US market (13x).


Price to Earnings Growth Ratio

PEG Ratio: ENTA is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: ENTA is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is Enanta Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

18.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ENTA's forecast earnings growth (18.9% per year) is above the savings rate (1.7%).

Earnings vs Market: ENTA's earnings (18.9% per year) are forecast to grow faster than the US market (12.3% per year).

High Growth Earnings: ENTA's earnings are forecast to grow, but not significantly.

Revenue vs Market: ENTA's revenue (14% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: ENTA's revenue (14% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ENTA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Enanta Pharmaceuticals performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ENTA has high quality earnings.

Growing Profit Margin: ENTA's current net profit margins (18%) are lower than last year (36.2%).


Past Earnings Growth Analysis

Earnings Trend: ENTA's earnings have declined by -3.9% per year over the past 5 years.

Accelerating Growth: ENTA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ENTA had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Biotechs industry average (22%).


Return on Equity

High ROE: ENTA's Return on Equity (7%) is considered low.


Next Steps

Financial Health

How is Enanta Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ENTA's short term assets ($440.5M) exceed its short term liabilities ($19.1M).

Long Term Liabilities: ENTA's short term assets ($440.5M) exceed its long term liabilities ($9.5M).


Debt to Equity History and Analysis

Debt Level: ENTA's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: ENTA's debt to equity ratio has increased from 0.09% to 0.3% over the past 5 years.

Debt Coverage: ENTA's debt is well covered by operating cash flow (3287.9%).

Interest Coverage: ENTA earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: ENTA has a low level of unsold assets or inventory.

Debt Coverage by Assets: ENTA's debt is covered by short term assets (assets are 270.6x debt).


Next Steps

Dividend

What is Enanta Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ENTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ENTA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ENTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ENTA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ENTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

16.5yrs

Average management tenure


CEO

Jay Luly (63yo)

16.67s

Tenure

US$4,483,503

Compensation

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxford Bioscien ...


CEO Compensation Analysis

Compensation vs Market: Jay's total compensation ($USD4.48M) is above average for companies of similar size in the US market ($USD3.12M).

Compensation vs Earnings: Jay's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jay Luly
President16.67yrsUS$4.48m3.26% $30.6m
Paul Mellett
Senior VP of Finance & Administration and CFO16.5yrsUS$1.53m0.21% $1.9m
Yat Or
Senior VP of Research & Development and Chief Scientific Officer20.33yrsUS$1.63m1.54% $14.4m
Nathaniel Gardiner
Senior VP5.83yrsUS$1.49m0.22% $2.1m
Nathalie Adda
Senior VP & Chief Medical Officer4.75yrsUS$1.61m0.078% $735.3k
Carol Miceli
Director of Investor Relationsno datano datano data

16.5yrs

Average Tenure

64yo

Average Age

Experienced Management: ENTA's management team is seasoned and experienced (16.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jay Luly
President16.67yrsUS$4.48m3.26% $30.6m
Bruce L. Carter
Independent Non-Executive Chairman4.25yrsUS$351.58kno data
Terry Vance
Independent Director8.75yrsUS$332.00k0.077% $719.4k
Kristine Peterson
Independent Director2.5yrsUS$317.00kno data
George Golumbeski
Independent Director6yrsUS$324.50kno data
Lesley Russell
Independent Director3.33yrsUS$319.50kno data

5.1yrs

Average Tenure

61.5yo

Average Age

Experienced Board: ENTA's board of directors are considered experienced (5.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Enanta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Enanta Pharmaceuticals, Inc.
  • Ticker: ENTA
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$937.046m
  • Shares outstanding: 19.92m
  • Website: https://www.enanta.com

Number of Employees


Location

  • Enanta Pharmaceuticals, Inc.
  • 500 Arsenal Street
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ENTANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2013
9EPDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2013
9EPBRSE (Berne Stock Exchange)YesCommon StockCHCHFMar 2013

Biography

Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 04:23
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.